Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04322084 | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL) | withdrawn | — | 0 | St. Jude Children's Research HospitalOTHER | 1 | Sep 25, 2024 |
| clinicaltrials |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT00756795 | Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)(I-PAP) | withdrawn | N/A | 0 | University of NebraskaOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors(SPICE) | withdrawn | — | 0 | University of CologneOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | withdrawn | Phase 3 | 0 | Johannes Laengle, MD, PhDOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT01174615 | Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth | withdrawn | — | 0 | University of Massachusetts, WorcesterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02745197 | A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer | withdrawn | Phase 2 | 0 | University of AlbertaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05757843 | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05849142 | Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac(OPC-V) | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06024941 | Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer(Re-Induce 2) | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06064279 | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC(HAITEN-ICI) | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT03003195 | The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 3, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05375253 | Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06372574 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | withdrawn | Phase 1 | 0 | Genentech, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT04996745 | Taking POSNA's OrthoKids to the People | withdrawn | N/A | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02249520 | Calibration of MR and PET-MR Imaging Protocols at RIC | withdrawn | N/A | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06054308 | Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study(CART) | withdrawn | N/A | 0 | Chinese University of Hong KongOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05450393 | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study) | withdrawn | — | 0 | Medtronic - MITGINDUSTRY | 0 | Aug 19, 2024 | clinicaltrials |
| NCT05112458 | Cope 360 App for Caregivers of Children With Cancer | withdrawn | N/A | 0 | Indiana UniversityOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06252727 | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) | withdrawn | Phase 1 | 0 | University of California, DavisOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06518538 | Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 15, 2024 | clinicaltrials |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04023240 | 68-Ga-FAPI PET Imaging in Malignancy | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | withdrawn | N/A | 0 | Australasian Leukaemia and Lymphoma GroupOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04880369 | Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression(DAGMAR) | withdrawn | N/A | 0 | Danish Cancer SocietyOTHER | 0 | Aug 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 26, 2024source: clinicaltrials